GLSI Greenwich LifeSciences, Inc.

$16.80

Greenwich LifeSciences, Inc. (GLSI) is expected to report earnings on November 10, 2026, before the market open. The consensus earnings estimate is a loss of $0.34 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +5.9% since its last earnings release on August 11, 2026.

Greenwich LifeSciences Beat Consensus Estimates
Tuesday, August 11, 2026 · 12:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 10
Tuesday · Before Open
Earnings Whisper
-
vs ($0.34)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $16.52

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences Inc. is a clinical stage biopharmaceutical company focuses on the development of cancer immunotherapies for breast cancer and other human epidermal growth factor. The company's product candidate includes GP2, which is in clinical stage. Greenwich LifeSciences Inc.is based in Stafford, Texas.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow